logo

SABS

SAB Biotherapeutics·NASDAQ
--
--(--)
--
--(--)
7.30 / 10
Outperform

The fund flow profile scores 7.42/10, demonstrating robust fund flow characteristics. Favorable no significant trends movements are tempered by challenging overall, block, Small, Medium, Large, and Extra-large dynamics, supporting positive flow assessment. Professional analyst opinion suggests overwhelmingly bullish analyst consensus, showing strong conviction. Distribution pattern: Strong Buy(100.0%) based on 2 research evaluations, supported by 7.18 historical weighted rating.

FundamentalSentiment(7.3)Technical
Fund Flow Rating
Analyst RatingStrong Buy

Wall Street Opinions

Strong Buy

Strong Buy

100%

Buy

0%

Hold

0%

Sell

0%

Strong Sell

0%

Date2026-03-10
InstitutionHC Wainwright & Co.
Times predicted3
Historical Win Rate33.3%
What is the analyst consensus for SABS?
  • SABS holds a Bullish analyst rating, with 100% of experts assigning a Strong Buy grade. Factoring in net Outflows from order flow data, the comprehensive Sentiment Score stands at 7.30/10 (Outperform).